Spectrum Pharmaceuticals Inc
F:NTR
Fundamental Analysis

Revenue & Expenses Breakdown
Spectrum Pharmaceuticals Inc
Balance Sheet Decomposition
Spectrum Pharmaceuticals Inc
Current Assets | 105.4m |
Cash & Short-Term Investments | 56.1m |
Receivables | 33.6m |
Other Current Assets | 15.6m |
Non-Current Assets | 2.3m |
PP&E | 2.1m |
Other Non-Current Assets | 245k |
Free Cash Flow Analysis
Spectrum Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Spectrum Pharmaceuticals Inc
Revenue
|
25.7m
USD
|
Cost of Revenue
|
-2.9m
USD
|
Gross Profit
|
22.9m
USD
|
Operating Expenses
|
-86.4m
USD
|
Operating Income
|
-63.5m
USD
|
Other Expenses
|
-1.5m
USD
|
Net Income
|
-65m
USD
|
NTR Profitability Score
Profitability Due Diligence
Spectrum Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Spectrum Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
NTR Solvency Score
Solvency Due Diligence
Spectrum Pharmaceuticals Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Spectrum Pharmaceuticals Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NTR Price Targets Summary
Spectrum Pharmaceuticals Inc
Dividends
Current shareholder yield for NTR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?